Chromocell Therapeutics (CHRO) vs. Its Competitors Head-To-Head Survey

Chromocell Therapeutics (NYSE:CHRO) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Chromocell Therapeutics to similar companies based on the strength of its institutional ownership, profitability, risk, analyst recommendations, dividends, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Chromocell Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chromocell Therapeutics	0	0	1	0	3.00
Chromocell Therapeutics Competitors	2005	5527	14213	312	2.58

As a group, “Biological products, except diagnostic” companies have a potential upside of 131.64%. Given Chromocell Therapeutics’ peers higher probable upside, analysts clearly believe Chromocell Therapeutics has less favorable growth aspects than its peers.

Institutional & Insider Ownership

78.0% of Chromocell Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.4% of Chromocell Therapeutics shares are owned by company insiders. Comparatively, 15.6% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Chromocell Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Chromocell Therapeutics	N/A	-$7.38 million	-0.77
Chromocell Therapeutics Competitors	$584.99 million	-$70.96 million	3.32

Chromocell Therapeutics’ peers have higher revenue, but lower earnings than Chromocell Therapeutics. Chromocell Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Chromocell Therapeutics has a beta of 4.59, suggesting that its stock price is 359% more volatile than the S&P 500. Comparatively, Chromocell Therapeutics’ peers have a beta of -4.57, suggesting that their average stock price is 557% less volatile than the S&P 500.

Profitability

This table compares Chromocell Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chromocell Therapeutics	N/A	N/A	-453.90%
Chromocell Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Summary

Chromocell Therapeutics beats its peers on 8 of the 13 factors compared.

About Chromocell Therapeutics

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.